Xeltis Showcases aXess Graft as Pivotal Trials Advance Toward Commercialization

According to a recent LinkedIn post from Xeltis, the company participated in the 29th European Vascular Course in Maastricht, where multiple scientific presentations referenced its aXess bioabsorbable arteriovenous graft. The post notes that clinicians discussed aXess in the context of vascular access creation, bioabsorbable graft technology, and cannulation innovations, while Xeltis staff engaged visitors at the company’s booth.

The post suggests that Xeltis is positioning aXess as a key asset in regenerative vascular access, with pivotal trials reported as ongoing in both the E.U. and U.S. If these studies progress successfully, the heightened visibility among vascular access specialists could support future adoption at commercialization, potentially strengthening Xeltis’s competitive position in the dialysis access market and enhancing its long‑term revenue prospects.